Product logins

Find logins to all Clarivate products below.


Parkinson’s Disease – Emerging Therapies – Special Topics: Novel Entrants in the Parkinson’s Disease Market (US)

Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g., dopamine agonists, MAO-B inhibitors) to address breakthrough motor symptoms. Pipeline therapies seek to improve therapeutic experience and motor symptom benefit through novel mechanisms, delivery routes, and simplified dosing regimens. The use of newer brands (e.g., Rytary [Amneal], Gocovri [Supernus], Inbrija [Acorda]) has steadily grown, but these agents will face competition from emerging reformulations (e.g., ABBV-951 [AbbVie]) and new molecular entities (NMEs) (IPX-203 [Amneal], dipraglurant [Addex], tavapadon [Cerevel]) in established classes; these reformulations and NMEs have the potential to radically change the clinical management and commercial outlooks in PD. Understanding physicians’ receptivity and anticipated use for new entrants is crucial for developers advancing new drugs in the increasingly crowded, largely generic, and clinically complex market.

Questions answered:

  • How have recently launched brands impacted the market? What are the reasons for prescribing or not prescribing key therapies?
  • How do neurologists rate the performance of key branded therapies?
  • How do neurologists view the clinical profiles of novel therapies for primary motor symptoms, motor fluctuations, and levodopa-induced dyskinesia (LID)? Which will they prefer, and how do they plan to incorporate these agents in treatment?
  • Why will physicians refrain from prescribing emerging brands?

Product description:

Clarivate’s Special Topics reports use quantitative and/or qualitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report will help developers gauge the competitiveness and sales potential of late-phase assets in the PD market.

Related Market Assessment Reports

Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…